Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort

BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn’s disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Inflamm Bowel Dis
Autors principals: Negoescu, Diana M, Enns, Eva A, Swanhorst, Brooke, Baumgartner, Bonnie, Campbell, James P, Osterman, Mark T, Papamichael, Konstantinos, Cheifetz, Adam S, Vaughn, Byron P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Clinical Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905301/
https://ncbi.nlm.nih.gov/pubmed/31184366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izz113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars